ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2389 • 2014 ACR/ARHP Annual Meeting

    MRI Osteitis at Baseline Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis

    Yoshikazu Nakashima1, Mami Tamai2, Junko Kita3, Sousuke Tsuji1, Shoichi Fukui1, Masataka Umeda1, Ayako Nishino1, Takahisa Suzuki1, Yoshiro Horai1, Akitomo Okada4, Tomohiro Koga1, Shinya Kawashiri5, Naoki Iwamoto1, Kunihiro Ichinose1, Yasuko Hirai1, Kazuhiko Arima5, Hideki Nakamura1, Tomoki Origuchi6, Masataka Uetani7, Kiyoshi Aoyagi5, Katsumi Eguchi8 and Atsushi Kawakami1, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 5Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 6Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 7Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Sasebo City General Hospital, Sasebo, Japan

    Background/Purpose: EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis (RA) states that magnetic resonance imaging (MRI)…
  • Abstract Number: 2390 • 2014 ACR/ARHP Annual Meeting

    Determinants and Impact of Early Initiation of Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis

    Chandana Keshavamurthy1, Kevin Kuriakose2, Deepak Chandra2, Aneet Kaur2, Horace Spencer2 and Nasim A. Khan3, 1Division of Rheumatology, University of Arkansas for Medical Sciences, Little Rock, AR, 2University of Arkansas for Medical Sciences, Little Rock, AR, 3Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR

    Background/Purpose Early initiation of disease-modifying anti-rheumatic drug (DMARD) therapy is recommended to improve rheumatoid arthritis (RA) outcomes. The aim of this study was to determine…
  • Abstract Number: 2391 • 2014 ACR/ARHP Annual Meeting

    Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice

    G. Avila1, Arnald Alonso1, María América López-Lasanta1, Andrea Pluma-Sanjurjo2, C. Diaz2 and Sara Marsal1, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain

    Background/Purpose Biological therapies (BTs) have greatly improved the outcomes in RA patients and nowadays clinical remission (REM) and low disease activity (LDA) have become realistic…
  • Abstract Number: 2392 • 2014 ACR/ARHP Annual Meeting

    Anti-Carbamylated Antibodies (anti-CarPA) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR)

    Jenny H. Humphreys1, Marije K Verheul2, Anne Barton3,4, Tarnya Marshall5, Bo Fu6, René E.M. Toes7, Deborah PM Symmons1,4, Leendert A. Trouw7 and Suzanne MM Verstappen1, 1Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, 4NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, 6Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, 7Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Anti-CarPA have been shown to predict development of rheumatoid arthritis (RA) in patients with arthralgia.  However, little is known about their association with disease…
  • Abstract Number: 2353 • 2014 ACR/ARHP Annual Meeting

    The Nitric Oxide Receptor Soluble Guanylyl Cyclase Is Found in Lymphatic Vessels of Arthritic Mice and Inhibition Alters Lymphatic Pulse

    Homaira Rahimi1, Yawen Ju2, Echoe M. Bouta3, Ronald Wood4, Christopher T. Ritchlin5 and Edward M. Schwarz6, 1Rheumatology, University of Rochester/Golisano Children's Hospit, Rochester, NY, 2Univ of Rochester Med Ctr, University of Rochester, Rochester, NY, 3University of Rochester School of Medicine and Dentistry, Rochester, NY, 4Department of Urology, University of Rochester Medical Center, Rochester, NY, 5Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, 6Center for Musculoskeletal Research, University of Rochester, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic erosive inflammatory condition that is characterized by episodes of “flare” due to synovitis of an affected joint. It…
  • Abstract Number: 2354 • 2014 ACR/ARHP Annual Meeting

    Efficacy of a Novel Orally Bioavailable JAK1 Selective Compound in a Preclinical Rat Collagen-Induced Arthritis Model

    Lily Y. Moy1, Chi-Sung Chiu1, Robert Faltus1, Mark Zielstorff2, Kalyan Chakravarthy1, Sujal Deshmukh1, Ilona Kariv1, Joel Klappenbach1, Jason Brubaker1, Duan Liu1, Tony Siu1, Jonathan Young1, Hongshi Yu1, Fiona Elwood1 and Milenko Cicmil1, 1Merck Research Laboratories, Boston, MA, 2Pharmacology, Merck Research Laboratories, Boston, MA

    Background/Purpose Janus kinase (JAK) is a family of four tyrosine kinases that play a critical role in cytokine signaling and downstream lymphocyte activation and function. …
  • Abstract Number: 2355 • 2014 ACR/ARHP Annual Meeting

    Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro

    Miguel Perez-Aso1, M. Carmen Montesinos2, Aranzazu Mediero3, Peter H. Schafer4 and Bruce N. Cronstein5, 1545 1st Ave., New York University, New York City, NY, 2Departament de Farmacologia, Facultat de Farmàcia,, Universitat de València, Valencia, Spain, 3Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 4Celgene Corporation, Celgene Corporation, Summit, NJ, 5NYU School of Medicine, Division of Rheumatology, New York, NY

    Background/Purpose Phosphodiesterase 4 (PDE4) inhibitors have clear immunoregulatory effects in laboratory studies, and the clinical application of this class of drug in the field of…
  • Abstract Number: 2356 • 2014 ACR/ARHP Annual Meeting

    Toluenesulfonylamido-Chalcone, 4-(p-toluenesulfonylamido)-4-Hydroxychalcone (TSAHC) Suppresses Inflammatory Response and Joint Destruction in an Experimental Arthritic Mice and Fibroblast-like Synoviocytes

    Yun-Hong Cheon1, Wan-Hee Yoo2, Young Sun Suh3, Min-Gyu Jeon4, Hyun-Ok Kim3 and Sang-Il Lee3, 1Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Chonbuk National University School of Medicine, Jeonju, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, 4Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, South Korea

    Background/Purpose  TSAHC, a toluenesulfonylamido-chalcone, 4-(p-toluenesulfonylamido)-4-hydroxychalcone is a compound to block proliferation and metastatic potential of cancer cells. Fibroblast-like synoviocytes of rheumatoid arthritis (RA-FLS) have inflammatory…
  • Abstract Number: 2357 • 2014 ACR/ARHP Annual Meeting

    Vascular Adhesion Molecule-1 Overexpression in Collagen-Induced Arthritis: Modeling Vascular Dysfunction in Rheumatoid Arthritis

    Luca Semerano1,2, Gaelle Clavel3, Delphine Lemeiter4, Marie-Christophe Boissier4,5 and Anne Denys1, 1INSERM UMR U1125, University Paris 13, Sorbonne Paris Cité, Bobigny, France, 2Rheumatology, Avicenne Teaching Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP),, Bobigny, France, 3Fondation Ophtalmologique A. De Rothschild, Paris cedex 19, France, 4INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France, 5Rheumatology, AvicenneTeaching Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France

     Vascular adhesion molecule-1 Overexpression in collagen-induced arthritis: modeling vascular dysfunctionS in rheumatoid arthritis    Background/Purpose: Rheumatoid Arthritis (RA) patients are at risk of developing primary coronary…
  • Abstract Number: 2358 • 2014 ACR/ARHP Annual Meeting

    The Role of Dendritic Cells during Inflammatory Arthritis

    Antonia Puchner1, Victoria Saferding2, Eliana Goncalves-Alves3, Josef Smolen4, Kurt Redlich5 and Stephan Blüml1, 1Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3rheumatology, Medical University of Vienna, Vienna, Austria, 4Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 5Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose Dendritic cells (DCs) play an important role in bridging the innate and the adaptive immune response by serving as antigen presenting cells and are…
  • Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting

    CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis

    Iris Hecht1, Kay McNamee2, Aviad Keren3, Joseph R. Podojil4, Ilan Vaknin1, Anat Oren1, Galit Rotman1, Eyal Neria1, Stephen D. Miller4, Amos Gilhar3 and Richard O. Williams2, 1Compugen Ltd., Tel Aviv, Israel, 2Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, 3Technion Institute of Technology, Haifa, Israel, 4Microbiology-Immunology, Northwestern University, Chicago, IL

    Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…
  • Abstract Number: 2360 • 2014 ACR/ARHP Annual Meeting

    Glucocorticoids and Vascular Function in Arthritis: Benefic or Deleterious Effects? Study in Rat

    Frank Verhoeven1, Katy Maguin-Gaté2, Perle Totoson3, Daniel Wendling4 and Céline Demougeot5, 1Rheumatology, CHU jean Minjoz, Besançon, France, 2EA 4267 « Fonctions et Dysfonctions Epithéliales » , Faculté de Médecine-Pharmacie, Besançon, France, 3UFR Sciences Médicales et Pharmaceutiques, EA 4267 "Fonctions et Dysfonctions Epithéliales", besançon, France, 4Service de Rhumatologie, CHU J Minjoz, Besancon, France, 5UFR Sciences Médicales et Pharmaceutiques, EA 4267 "Fonctions et Dysfonctions Epithéliales", Besançon, France

    Background/Purpose: Rheumatoid Arthritis (RA) is associated to an increase of cardiovascular (CV) risk explained in part by an accelerated atherosclerosis as a consequence of endothelial…
  • Abstract Number: 2361 • 2014 ACR/ARHP Annual Meeting

    the Role of CD146 in the Therapeutic Potential of Mesenchymal Stem Cells in Favor of CD146+ Cells for Experimental Arthritis

    Deh-Ming Chang1 and Cheng-Chi Wu2, 1Rheumatology/Immunology, Taipei Veteran's General Hospital, Taipei, Taiwan, 2National Defense Medical Center, Taipei, Taiwan

    Background/Purpose:  To illustrate whether the subtypes of mesenchymal stem cells (MSCs) have different cellular characteristics and therapeutic potentials, we separated CD146+/- mesenchymal stem cells and…
  • Abstract Number: 2362 • 2014 ACR/ARHP Annual Meeting

    Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model

    Rebecca A. Bader, David R. Wilson, Arundhati Ramani and Patricia R. Wardwell, Biomedical & Chemical Engineering, Syracuse University, Syracuse, NY

    Background/Purpose:  A number of conventional, disease modifying anti-rheumatic drugs (DMARDs) are associated with severe side effects due to non-specific targeting and impaired immune function. To…
  • Abstract Number: 2363 • 2014 ACR/ARHP Annual Meeting

    Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease Activity Marker Under IL-6 Suppression in Autoimmune Arthritis

    Yusuke Takahashi1, Minoru Fujimoto2, Satoshi Serada3 and Tetsuji Naka2, 1a doctoral student, Osaka university, Suita city, Japan, 2Laboratory for immune signal, National Institute of Biomedical Innovation, Ibaraki, Japan, 37-6-8, Saito-asagi, National Institute of Biomedical Innovation, Laboratory for immune signal, Japan, Ibaraki, Japan

    Background/Purpose  C-reactive protein (CRP) is frequently used to evaluate inflammation in patients with rheumatoid arthritis (RA). However, CRP is normalized when IL-6 function is potently…
  • « Previous Page
  • 1
  • …
  • 2074
  • 2075
  • 2076
  • 2077
  • 2078
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology